Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
News
Recent Posts
- ALS Nexus 2026: Implantable device decodes patients’ brain signals
- ALS Nexus 2026: People with diabetes may have lower ALS risk, study says
- $1 million grant supports trial of experimental treatment for ALS
- Higher physical activity tied to lower ALS risk in large UK study
- Those earlier years with ALS seem like a different life